Asset Details
Do you wish to reserve the book?
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
Do you wish to request the book?
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
2011
Overview
In this clinical trial involving patients with established cardiovascular disease, the addition of niacin to intensive statin therapy provided no additional clinical benefit over a period of 3 years, despite favorable changes in lipid levels.
More than 18 million North Americans have coronary heart disease, and despite profound advances in both pharmacologic and interventional management, both morbidity and mortality remain appreciable.
1
,
2
Elevated low-density lipoprotein (LDL) cholesterol levels are an established predictor of the risk of coronary heart disease. Multiple primary and secondary prevention trials have shown a significant reduction of 25 to 35% in the risk of cardiovascular events with statin therapy
3
; however, residual risk persists despite the achievement of target LDL cholesterol levels.
Epidemiologic studies have shown that, in addition to elevated LDL cholesterol levels, low levels of high-density lipoprotein (HDL) cholesterol . . .
Publisher
Massachusetts Medical Society
Subject
/ Atherosclerosis - drug therapy
/ Biological and medical sciences
/ Brain Ischemia - chemically induced
/ Brain Ischemia - epidemiology
/ Cardiovascular Diseases - epidemiology
/ Cardiovascular Diseases - mortality
/ Diet
/ Disorders of blood lipids. Hyperlipoproteinemia
/ Female
/ Humans
/ Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use
/ Hypolipidemic Agents - adverse effects
/ Hypolipidemic Agents - therapeutic use
/ Ischemia
/ Male
/ Muscular Diseases - chemically induced
/ Simvastatin - therapeutic use
/ Statins
/ Stroke
